Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 1,387

Document Document Title
WO/1987/005289A1
A biarylic coupling method, the ruthenium catalyst for its implementation and the new compound resulting therefrom. The biarylic coupling method according to the invention is characterized in that the biarylic precursors are cycled in th...  
WO/1984/003702A1
Benzoquinolizines of general formula (I) and their pharmaceutically acceptable acid addition salts. In formula (I), R represents hydrogen or lower alkyl, R1 and R2 which may be the same or different each represent hydrogen, lower alkyl, ...  
WO/1984/002342A1
Laevogyrous enantiomers of tetrahydro-5,6,13,13a-8H-dibenzo ADa,g BD-quinolizine derivatives having the formula (III), wherein R'3 is hydrogen, an alkyl or aryl group or a radical -OR or -SR, R being hydrogen, an alkyl or aryl group or a...  
WO/1983/002612A1
A method of preparing a compound of the general formula$(10,) which: R1 and R2 independently represent a hydrogen atom, an alkyl or substituted alkyl group, an aryl or substituted aryl group, an aralkyl or substituted aralkyl group, a cy...  
JP2021046454A
【課題】化合物の調製のための合成方法を提 供すること。【解決手段】(S)−(2R, 3R,11bR)−3−イソブチル−9,1 0−ジメトキシ−2,3,4,6,7,...  
JP2021508712A
本発明は、一般式(式中、R1、R2、X、 Y、及びAは、本明細書に記載される通りで ある)を有する新規化合物、該化合物が含ま れる組成物、及び該化合物を使用する方...  
JP2021507927A
A crystalline form of barbenazintosylate and a method for producing the same, a pharmaceutical composition containing the crystalline form, and the crystalline form for producing a preparation of a vesicular monoamine transporter 2 inhib...  
JP2021502987A
The present invention relates to compounds useful in the prevention and / or treatment of one or more fibrous diseases. In particular, the compounds of the invention antagonize the G protein-coupled receptor GPR84. The present invention ...  
JP6786599B2
The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of gene...  
JP6783329B2
The present invention provides a mangiferin-6-O-calcium salt and a preparation process thereof. In addition, use of the mangiferin-6-O-calcium salt as defined in claim 1 as an intermediate in the preparation of a mangiferin-6-O-berberine...  
JP2020530483A
The present invention relates to tetrahydroprotoberberine compounds represented by the general formula (I), their enantiomers, diastereomers, racemates and mixtures thereof, and pharmacologically acceptable inorganic or organic salts the...  
JP6755254B2
wherein R1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compound...  
JP2020128367A
To provide a compound excellent in the luminance life of a light emitting element.An example of the invention is the following compound E-Cs.SELECTED DRAWING: None  
JP2020522469A
The present invention relates to deuterated compounds according to Formula IA, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET contrast agents to assess Parkinson's disease, Alzheimer's disease, and to d...  
JP6733449B2
A method for producing a berberine alkaloid which can efficiently produce a berberine alkaloid can be provided.The method for producing theberberine alkaloid is characterized by comprising thefollow procedures of conducting intramolecula...  
JP2020519654A
Generally the present invention relates to berberine ursodeoxycholic acid of a solid form, its medicine constituent, a preparing method for the same, and its therapeutic use. When especially the present invention treats and/or prevents v...  
JP6716462B2
The present invention relates to a cyclic amine surface modifier. In addition the present invention also relates to organic electronic devices comprising such cyclic amine surface modifier.  
JP2020512986A
The present invention relates to use of low-dose (+)-alpha-dihydrotetra-Benazine for the medical treatment of motility disturbance, such as a Tourette's syndrome. The present invention provides (+)-alpha-dihydrotetra-Benazine for using i...  
JP2020512988A
The present invention provides (+)-alpha-dihydrotetra-Benazine succinic acid salt. (+)-alpha-dihydrotetra-Benazine succinic acid salt for using it for medical supplies, The medicine constituent containing (+)-alpha-dihydrotetra-Benazine ...  
JPWO2018159662A1
The compound which has the structure denoted by the following general formula is useful as a luminescent material. R1~R9At least one of is substitution machine;Y.1~Y3Is methylene machine, carbonyl group, thiocarbonyl group, imino group, ...  
JP2020508337A
The present invention relates to the crystalline hydrate of crystalline Barbena Jinji tosylate, especially Barbena Jinji tosylate, the crystalline anhydride of Barbena Jinji tosylate, and its preparing method. The present invention relat...  
JP2020040949A
To provide novel high penetration compositions (HPCs) or high penetration prodrugs (HPPs) for treatment of Parkinson's disease.The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the bio...  
JP6654568B2
The present invention provides substituted berbines, processes for the synthesis of substituted berbine compounds preferably through a Bischler-Napieralski cyclization followed by reduction, as well as intermediates used in the synthesis...  
JP2020500875A
Being provided in this specification is (S)-2-amino 3-methylbutyric acid (2 R,3 R,11bR)-3-isobutyl 9,10. - Dimethoxy 1,3,4,6,7,11b-hexahydro 2H-pyrid [ 2,1-] [a] iso quinoline 2-Ilester, Or it is a method for dealing with schizophrenia o...  
JP2019531353A
The present invention relates to the salt permitted pharmacologically [the compound denoted by structural formula I, and its avirulence]. R1, R2, R3, and R4 are methyl groups (-CH) to each.3Or the Tori deuteration methyl group (-CD)3Bein...  
JP2019530667A
R1R2R3R4R5The compound of formula (I) which is as m, n, and p having been defined by this specification, N- Oxide , or its salt is indicated. The method of using this compound as inhibitor of Toru Mr. receptor 7 or the signal transfer th...  
JP6596483B2  
JP6577491B2
The present disclosure provides oxidized berbine derivatives, processes for their preparation, and methods of using the oxidized berbine derivatives.  
JP2019523261A
The Isoquinolinone system compound in which the present invention is shown at formula (I), its stereoisomeric form, The use in manufacture of the medicine which treats or prevents virus infectivity diseases, such as the salt and solvent ...  
JP2019519569A
The present invention provides Menguy Felin - 6-O-calcium salt and a preparing method for the same. The present invention provides the use of this Menguy Felin - 6-O-calcium salt as an intermediate in manufacture of Menguy Felin - 6-O-be...  
JP6542222B2
The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.  
JP6520440B2
To provide conventionally unknown, novel compounds, discovered from natural products, the compounds having pharmacological activity such as diabetes modulator (e.g. α-glucosidase) inhibitory action, radical removal action and LDL oxidat...  
JP6506880B2
wherein R1 to R6, V, W, X and Y are as described herein, compositions including the compounds and methods of using the compounds.  
JP2019509276A
The compound of formula (I) written in this specification with the salt in which the present invention is permitted pharmacologically, The method of using it in order to treat the infection caused by virus infection, especially the hepat...  
JP2019038987A
To provide a novel fluorescent dye agent.A fluorescent dye agent contains a carbostyril compound represented by formula (1) [in the formula (1), Ris H, a halogen atom, a hydroxyl group, a cyano group, a nitro group or the like; Ris O; Ri...  
JP6472068B2  
JP2019504039A
Inhibitor of TDO2 revealed by the cell and its pharmacological constituent are provided by this application. In order that these inhibitor and its pharmacological constituent may adjust the activity of tryptophan 2 and 3 dioxy Genase , I...  
JP6460498B2
The present invention provides a mangiferin-6-O-berberine salt and a preparation method thereof, and further provides a use of the mangiferin-6-O-berberine salt for the treatment of diabetics and other diseases as an AMPK activator.  
JP2019500372A
(S) - (2 R, 3 R, 11bR) -3-isobutyl 9, 10-dimethoxy 2, 3, 4, 6, 7, 11b-hexahydro -- 1H-pyrid [2, 1-a] iso quinoline 2- Il 2-amino 3-methyl pig Nootji (4-methylbenzene sulfonate) Or a process for preparing the solvent Japanese food , a hyd...  
JP2018536652A
The present invention relates to the field of medicine manufacture chemicals, and relates to a condensation heterocyclic compound derivative and its application particularly. It can be used for this condensation heterocyclic compound der...  
JP6435054B2
wherein R1, R2, R3, R4, R5 and Ar are as described herein, compositions including the compounds and methods of using the compounds.  
JP2018531963A
(S) -2-amino 3-methylbutyric acid (2 R, 3 R, 11bR) -3-isobutyl 9, 10 of an amorphous form and a crystalline form - Salt of dimethoxy 1, 3, 4, 6, 7, 11b-hexahydro 2H-pyrid [2, l-] [a] iso quinoline 2- Il Ester , And those manufacture proc...  
JP2018145423A
To provide a fluorescent dye that allow lipid metabolism into a cell and can distinction between a fatty acid metabolized to a cell membrane and a fatty acid metabolized to a lipid droplet.Provided is an azapyrene compound represented by...  
JP2018526336A
The present invention is a general formula (inside of a formula, R).1~R6as V, W, X, and Y having been written in this specification -- it is -- the method of using the constituent and compound containing the new compound which it has, an...  
JP6357167B2
This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure ...  
JP2018517666A
Ursodeoxycholic acid, eicosapentaenoic acid, or docosa-hexaenoic acid, Or Reign, R- (+) -alpha lipo acid, or Ur Saul acid, Or Collo Saul acid, hydroxy citrate, or cinnamic acid, Or cholic acid, oleanolic acid, or salicylic acid, Or betul...  
JP2017518987A5  
JP2018065866A
To provide novel high penetration compositions (HPCs) or high penetration prodrugs (HPPs) for treatment of Parkinson's disease.The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the bio...  
JP2018510845A
The field of this indication is in the active material of an organic image sensor. This indication is related with those use in squaraine, Thiophene system active material and a photoelectric conversion layer (plurality is good), and/or ...  
JPWO2016199789A1
In order to manufacture various functional trifluoromethyl compounds, let it be subjects a short process and to compound efficiently for a trifluoromethyl substitution semi Squares rate. The method of compounding a trifluoromethyl substi...  

Matches 351 - 400 out of 1,387